Randomized control trial of intravenous acetaminophen for reduction of intrapartum maternal fever

Background Intravenous acetaminophen reaches a higher mean peak plasma concentration than oral in shorter period of time. The favorable pharmacokinetics intravenous may be beneficial for treating intrapartum maternal fever. Objective primary objective was to compare and time defervescence (temperature <38°C). secondary the percentage participants being afebrile percent reduction temperature 30 minutes after administration first dose. Other outcomes evaluated were histopathological placental findings; neonatal outcomes; oxidative stress; levels RANTES, interferon-?, interleukin 1?, 2, 4, 6, 8, 10, 13, tumor necrosis factor-? blood. Study Design This randomized, comparator-controlled, double-dummy, double-blind clinical trial. At onset fever ?38°C, patients ?36 weeks’ gestation either randomized control or experimental study arm. Patients arm received 1000 mg capsules an placebo resembling acetaminophen. Maternal temperatures fetal heart rates recorded at consecutive intervals following dose blood, collected delivery, cord blood delivery stress (glutathione levels), RANTES cytokines (interferon-?, factor-?). Placentas pathologic review. A P value <.05 considered statically significant. Results total 121 (55 66 group) recruited from December 1, 2016, February 28, 2018. Patient demographics factors similar between both arms. group showed 54.86 (95% confidence interval, 20.57–39.43) vs 52.58 16.58–43.42) (P=.71). In addition, results Histopathological findings, outcomes, markers, cytokine not statistically significant groups. Conclusion did demonstrate efficacy Select benefit treatment fever, including those who cannot tolerate medication.